Related references
Note: Only part of the references are listed.Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability
Tong Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Emerging strategies for treating gout
Edward M. Huddleston et al.
CURRENT OPINION IN PHARMACOLOGY (2022)
Treatment advances in gout
Lisa K. Stamp et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2021)
Recent Updates of Natural and Synthetic URAT1 Inhibitors and Novel Screening Methods
Ying Chen et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2021)
Loganin Alleviates Gout Inflammation by Suppressing NLRP3 Inflammasome Activation and Mitochondrial Damage
Nuri Choi et al.
MOLECULES (2021)
A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications
Danni Song et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
Shizhen Zhao et al.
RSC ADVANCES (2021)
Therapeutic approaches in the treatment of gout
Michael H. Pillinger et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Design, synthesis and structure-activity relationship studies of novel partial FXR agonists for the treatment of fatty liver
Qianqian Qiu et al.
BIOORGANIC CHEMISTRY (2020)
Systematic Structure-Activity Relationship (SAR) Exploration of Diarylmethane Backbone and Discovery of A Highly Potent Novel Uric Acid Transporter 1 (URAT1) Inhibitor
Wenqing Cai et al.
MOLECULES (2018)
Lesinurad: A Review in Hyperuricaemia of Gout
Emma D. Deeks
DRUGS & AGING (2017)
Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis
Haiping Hao et al.
CELL METABOLISM (2017)
Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis
Fredrik Nyberg et al.
ADVANCES IN THERAPY (2016)
Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome
Chul-Su Yang et al.
NATURE COMMUNICATIONS (2015)
The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study
Emma Smith et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The pharmacokinetics of oxypurinol in people with gout
Sophie L. Stocker et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
N-(1,3-Diaryl-3-oxopropyl)amides as a new template for xanthine oxidase inhibitors
Kunal Nepali et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Synthesis of some 5-phenylisoxazole-3-carboxylic acid derivatives as potent xanthine oxidase inhibitors
Shaojie Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Prevalence of the metabolic syndrome in individuals with hyperuricemia
Hyon K. Choi et al.
AMERICAN JOURNAL OF MEDICINE (2007)